ArticleFuture science OA2019
Medication persistence for psoriatic arthritis in a Brazilian real-world setting.
Article in Future science OA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.Advances in rheumatology (London, England) · 2024Pooled it
- Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis.EULAR rheumatology open · 2026Article
- Evaluation of the performance of biological drugs in the treatment of ankylosing spondylitis: cohort study, Minas Gerais, 2018-2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Gender Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey.Rheumatology and therapy · 2024Article
- Sex- and gender-related differences in psoriatic arthritis.Nature reviews. Rheumatology · 2022Review
- Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study.Frontiers in medicine · 2022Article
- Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil.Frontiers in pharmacology · 2022Article
- Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis-A Retrospective Database Study.Rheumatology and therapy · 2021Article
- Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden.Rheumatology advances in practice · 2020Article
- First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study.Sao Paulo medical journal = Revista paulista de medicinaObservational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]) antirheumatic agents for psoriatic arthritis and their associated factors.
methodsA historical cohort was developed. Persistence and associated factors were evaluated at 6 and 12 months.
resultsA total of 161 patients were included. The anti-TNF treatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4 vs 35.6%; p < 0.05). From anti-TNFs, adalimumab and etanercept presented similar persistence, along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence with regard to anti-TNF agents were female sex and use of infliximab.
conclusionAnti-TNF agents are important therapeutic alternatives and present lower rates of discontinuation as compared with csDMARDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.